Name (Synonyms) | Correlation | |
---|---|---|
drug2147 | Placebo for Hydroxychloroquine Wiki | 1.00 |
drug3508 | vadadustat Wiki | 1.00 |
drug2146 | Placebo for Azithromycin Wiki | 1.00 |
drug1285 | Hydroxychloroquine (HCQ) Wiki | 0.50 |
drug3408 | placebo Wiki | 0.27 |
Name (Synonyms) | Correlation | |
---|---|---|
D013577 | Syndrome NIH | 0.10 |
D055371 | Acute Lung Injury NIH | 0.10 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.09 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.08 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The purpose of this study is to evaluate the efficacy of hydroxychloroquine (HCQ) and azithromycin (Azithro) to prevent hospitalization or death in symptomatic adult outpatients with COVID-19 caused by SARS-CoV-2 infection.
Description: Hospitalization is defined as requiring at least 24 hours of acute care in a hospital or similar acute care facility, including Emergency Rooms or temporary facilities instituted to address needs during the COVID-19 pandemic. Evaluation at a hospital or similar facility with less than 24 hours of acute care is not considered a hospitalization.
Measure: Proportion of participants who died from any cause or were hospitalized Time: Measured during the 20-day period from and including the day of the first (confirmed) dose of study treatmentDescription: Hospitalization is defined as requiring at least 24 hours of acute care in a hospital or similar acute care facility, including Emergency Rooms or temporary facilities instituted to address needs during the COVID-19 pandemic. Evaluation at a hospital or similar facility with less than 24 hours of acute care is not considered a hospitalization.
Measure: Proportion of participants who died from any cause or were hospitalized through the end of follow-up Time: Measured during the 20-day period from and including the day of the first (confirmed) dose of study treatmentDescription: Defined as the last day in the participant's daily diary card on which a temperature greater than 100.4°F was recorded or a potentially antipyretic drug, such as acetaminophen or ibuprofen, was taken.
Measure: Duration of fever Time: Measured through Day 20Description: Defined as the last day in the participant's daily diary card on which a moderate or worse symptom was recorded
Measure: Duration of symptoms associated with COVID-19 disease Time: Measured through Day 20Description: Defined as the sum of scores for the targeted symptoms (defined in the protocol) in the participant's daily diary record (each individual symptom is scored from 0 to 3).
Measure: Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time Time: Measured through Day 20